PMID- 22626951
OWN - NLM
STAT- MEDLINE
DCOM- 20121130
LR  - 20120704
IS  - 1532-2777 (Electronic)
IS  - 0306-9877 (Linking)
VI  - 79
IP  - 2
DP  - 2012 Aug
TI  - Intranasal insulin-like growth factor I (IGF-I) as a plausible future treatment 
      of depression.
PG  - 222-5
LID - 10.1016/j.mehy.2012.04.045 [doi]
AB  - Depression remains a highly prevalent and mostly recurrent disorder causing an 
      increased need to optimize and broaden the current therapy options. An enormous 
      body of evidence links the regulation of specific neurotrophic proteins, like the 
      brain-derived neurotrophic factor (BDNF), to depression and it may be assumed 
      that the behavioral effects of antidepressants require functional BDNF signaling 
      in the brain. Another neurotrophin, insulin-like growth factor-I (IGF-I), also 
      produces antidepressant-like behavioral effects. Data have shown that BDNF plus 
      IGF-I are more effective than either neurotrophin alone in activating 
      neurotrophic cascades and promoting survival of hippocampal neurons. In fact, it 
      has been suggested that the increase in hippocampal BDNF following antidepressant 
      treatment or physical exercise in animal models is IGF-I-dependent and that 
      antidepressant treatment increases IGF-I in human cerebrospinal fluid (CSF). 
      Thus, BDNF and IGF-I seem to act synergistically in the same cascade of 
      transmission and neuroplasticity. In order to avoid the pitfalls of systemic 
      application (e.g. possible peripheral side effects) while directly targeting 
      central nervous circuitries, the clinical intranasal administration of IGF-I 
      appears to be a plausible and promising treatment option of depression.
CI  - Copyright (c) 2012 Elsevier Ltd. All rights reserved.
FAU - Paslakis, G
AU  - Paslakis G
AD  - Central Institute of Mental Health, Medical Faculty Mannheim, University of 
      Heidelberg, Mannheim, Germany. Georgios.Paslakis@zi-mannheim.de
FAU - Blum, W F
AU  - Blum WF
FAU - Deuschle, M
AU  - Deuschle M
LA  - eng
PT  - Journal Article
DEP - 20120523
PL  - United States
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Neuroprotective Agents)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
SB  - IM
MH  - Administration, Intranasal
MH  - Brain/drug effects/*physiopathology
MH  - Brain-Derived Neurotrophic Factor/*metabolism
MH  - Depression/*drug therapy/*physiopathology
MH  - Humans
MH  - Insulin-Like Growth Factor I/*administration & dosage
MH  - *Models, Neurological
MH  - Neuroprotective Agents/administration & dosage
EDAT- 2012/05/26 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/05/26 06:00
PHST- 2012/01/04 00:00 [received]
PHST- 2012/03/27 00:00 [revised]
PHST- 2012/04/27 00:00 [accepted]
PHST- 2012/05/26 06:00 [entrez]
PHST- 2012/05/26 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - S0306-9877(12)00210-1 [pii]
AID - 10.1016/j.mehy.2012.04.045 [doi]
PST - ppublish
SO  - Med Hypotheses. 2012 Aug;79(2):222-5. doi: 10.1016/j.mehy.2012.04.045. Epub 2012 
      May 23.